Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients

NCT02069704 is registered in ClinicalTrials.gov with mAbxience Research S.L. as lead sponsor.

NCT NCT02069704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02069704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients
Lead sponsor
mAbxience Research S.L.
Phase
Phase 1
Overall status
Completed
Start date
October 29, 2014
Completion date
June 30, 2017
Enrollment
142 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (mcrc)